Babiy V.V., Kulikov A.Y. 1193

Validation of the pharmacoeconomic model of emtricitabin/ rilpivirine/ tenofovir (eviplera) inclusion in highly active antiretroviral therapy of HIV/AIDS in the Russian Federation

The article deals with the results of validation of the pharmacoeconomic model of emtricitabin/ rilpivirine/ tenofovir (Eviplera) inclusion in highly active antiretroviral therapy of HIV/AIDS in the Russian Federation.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF

Comments0